JP2012513467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012513467A5 JP2012513467A5 JP2011543601A JP2011543601A JP2012513467A5 JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5 JP 2011543601 A JP2011543601 A JP 2011543601A JP 2011543601 A JP2011543601 A JP 2011543601A JP 2012513467 A5 JP2012513467 A5 JP 2012513467A5
- Authority
- JP
- Japan
- Prior art keywords
- resistant
- bacterium
- pharmaceutical composition
- clostridium difficile
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 241000193163 Clostridioides difficile Species 0.000 claims 10
- 108010013198 Daptomycin Proteins 0.000 claims 8
- 230000003115 biocidal effect Effects 0.000 claims 8
- 229960005484 daptomycin Drugs 0.000 claims 8
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical group C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims 8
- 208000035143 Bacterial infection Diseases 0.000 claims 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims 6
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims 4
- 101710172419 5-azacytidine-induced protein 2 Proteins 0.000 claims 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229960003085 meticillin Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 3
- 208000037384 Clostridium Infections Diseases 0.000 claims 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 2
- 206010054236 Clostridium difficile infection Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 229930182555 Penicillin Natural products 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229940049954 penicillin Drugs 0.000 claims 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 0 C*(C)c(cc1)ccc1C(C)=CC(C)=O Chemical compound C*(C)c(cc1)ccc1C(C)=CC(C)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13987508P | 2008-12-22 | 2008-12-22 | |
| US61/139,875 | 2008-12-22 | ||
| PCT/US2009/068747 WO2010075215A1 (en) | 2008-12-22 | 2009-12-18 | Novel antibacterial agents for the treatment of gram positive infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012513467A JP2012513467A (ja) | 2012-06-14 |
| JP2012513467A5 true JP2012513467A5 (enExample) | 2013-10-03 |
| JP5670914B2 JP5670914B2 (ja) | 2015-02-18 |
Family
ID=41718893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543601A Expired - Fee Related JP5670914B2 (ja) | 2008-12-22 | 2009-12-18 | グラム陽性菌感染症を処置するための新規抗菌剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8507647B2 (enExample) |
| EP (2) | EP2674437A1 (enExample) |
| JP (1) | JP5670914B2 (enExample) |
| KR (1) | KR101717795B1 (enExample) |
| CN (1) | CN102325787B (enExample) |
| AR (1) | AR074833A1 (enExample) |
| AU (1) | AU2009330245C1 (enExample) |
| BR (1) | BRPI0923567A2 (enExample) |
| CA (1) | CA2747965C (enExample) |
| CY (1) | CY1114883T1 (enExample) |
| DK (1) | DK2379580T3 (enExample) |
| ES (1) | ES2442167T3 (enExample) |
| HR (1) | HRP20131170T1 (enExample) |
| IL (1) | IL213638A0 (enExample) |
| MX (1) | MX2011006803A (enExample) |
| NZ (1) | NZ594019A (enExample) |
| PL (1) | PL2379580T3 (enExample) |
| PT (1) | PT2379580E (enExample) |
| RS (1) | RS53152B (enExample) |
| RU (1) | RU2512396C2 (enExample) |
| SG (1) | SG172299A1 (enExample) |
| SI (1) | SI2379580T1 (enExample) |
| SM (1) | SMT201400037B (enExample) |
| TW (1) | TWI444198B (enExample) |
| WO (1) | WO2010075215A1 (enExample) |
| ZA (1) | ZA201104693B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013157188A (ru) | 2011-05-26 | 2015-07-10 | Кьюбист Фармасьютикалз, Инк. | Композиции св-183,315 и относящиеся к ним способы |
| US10377699B2 (en) * | 2013-11-06 | 2019-08-13 | The University Of Hong Kong | Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue |
| WO2015172047A1 (en) * | 2014-05-08 | 2015-11-12 | Merck Sharp & Dohme Corp. | Cyclic peptide compounds and related methods, salts and compositions |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| MX386103B (es) * | 2016-04-22 | 2025-03-18 | Astrazeneca Ab | Inhibidores de mcl-1 y metodos de uso de los mismos. |
| US10098890B2 (en) | 2016-10-29 | 2018-10-16 | Cipla Limited | Stable carfilzomib formulations |
| IT201600127655A1 (it) * | 2016-12-16 | 2018-06-16 | Gnosis Spa | Processo per la purificazione di antibiotici lipopolipeptidici |
| US10072045B1 (en) | 2017-06-26 | 2018-09-11 | Ramapo Pharmaceuticals, Inc. | Antibacterial lipopeptides and methods for their preparation and use |
| US10526343B2 (en) | 2018-03-26 | 2020-01-07 | University Of Sharjah | Heterocyclic systems and pharmaceutical applications thereof |
| RU2762182C1 (ru) * | 2020-12-08 | 2021-12-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" | Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| USRE32333E (en) | 1978-10-16 | 1987-01-20 | Eli Lilly And Company | A-21978 Antibiotics and process for their production |
| USRE32455E (en) | 1978-10-16 | 1987-07-07 | Eli Lilly And Company | A-21978 antibiotics and process for their production |
| US4812470A (en) | 1982-02-27 | 1989-03-14 | Beecham Group P.L.C. | Antibacterial monic acid derivatives |
| US4399067A (en) | 1982-05-21 | 1983-08-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32311E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| USRE32310E (en) | 1982-05-21 | 1986-12-16 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4524135A (en) | 1982-05-21 | 1985-06-18 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4482487A (en) | 1982-05-21 | 1984-11-13 | Eli Lilly And Company | A-21978C cyclic peptides |
| US4396543A (en) * | 1982-05-21 | 1983-08-02 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| IL68700A0 (en) * | 1982-05-21 | 1983-09-30 | Lilly Co Eli | Improvements relating to a-21978c cyclic peptide derivatives and their production |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CS276978B6 (en) | 1984-10-09 | 1992-11-18 | Lilly Co Eli | Process for preparing a-21978c antibiotic derivative |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| US5039660A (en) | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
| CA2043762C (en) | 1990-06-07 | 2001-05-29 | Adam J. Kreuzman | Lipopeptide deacylase |
| AU7497594A (en) | 1993-08-13 | 1995-03-14 | Smithkline Beecham Plc | Derivatives of monic acids a and c having antibacterial, antimycoplasmatical, antifungal and herbicidal activity |
| DE4411025A1 (de) | 1994-03-30 | 1995-10-05 | Hoechst Ag | Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| CA2248348C (en) | 1996-03-08 | 2008-06-10 | Fujisawa Pharmaceutical Co., Ltd. | Process for the deacylation of cyclic lipopeptides |
| DE19807972A1 (de) | 1998-02-25 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung |
| HK1040363B (en) | 1998-09-25 | 2007-01-26 | Cubist Pharmaceuticals Llc | Use of daptomycin |
| JP2003520353A (ja) | 1999-11-03 | 2003-07-02 | ザ ウィタカー コーポレーション | マルチファイバアレー用光電子モジュール |
| WO2001044271A2 (en) | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Daptomycin analogs and their use as antibacterial agents |
| KR20020063228A (ko) | 1999-12-15 | 2002-08-01 | 큐비스트 파마슈티컬즈 인코포레이티드 | 항균제로서 리포펩티드 |
| US6911525B2 (en) * | 1999-12-15 | 2005-06-28 | Cubist Pharmaceuticals, Inc. | Lipopeptides as antibacterial agents |
| US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| EP1423137B1 (en) | 2001-08-06 | 2009-04-29 | Cubist Pharmaceuticals, Inc. | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates |
| EP1814588A2 (en) * | 2004-11-12 | 2007-08-08 | Cubist Pharmaceuticals, Inc. | Antiinfective lipopeptides |
-
2009
- 2009-12-18 RU RU2011130278/04A patent/RU2512396C2/ru not_active IP Right Cessation
- 2009-12-18 NZ NZ594019A patent/NZ594019A/xx not_active IP Right Cessation
- 2009-12-18 WO PCT/US2009/068747 patent/WO2010075215A1/en not_active Ceased
- 2009-12-18 DK DK09795876.3T patent/DK2379580T3/da active
- 2009-12-18 AU AU2009330245A patent/AU2009330245C1/en not_active Ceased
- 2009-12-18 PL PL09795876T patent/PL2379580T3/pl unknown
- 2009-12-18 BR BRPI0923567A patent/BRPI0923567A2/pt not_active Application Discontinuation
- 2009-12-18 PT PT97958763T patent/PT2379580E/pt unknown
- 2009-12-18 HR HRP20131170AT patent/HRP20131170T1/hr unknown
- 2009-12-18 RS RS20140021A patent/RS53152B/sr unknown
- 2009-12-18 EP EP13183732.0A patent/EP2674437A1/en not_active Withdrawn
- 2009-12-18 MX MX2011006803A patent/MX2011006803A/es active IP Right Grant
- 2009-12-18 US US12/641,465 patent/US8507647B2/en active Active
- 2009-12-18 JP JP2011543601A patent/JP5670914B2/ja not_active Expired - Fee Related
- 2009-12-18 ES ES09795876.3T patent/ES2442167T3/es active Active
- 2009-12-18 EP EP09795876.3A patent/EP2379580B1/en active Active
- 2009-12-18 SG SG2011045440A patent/SG172299A1/en unknown
- 2009-12-18 KR KR1020117017003A patent/KR101717795B1/ko not_active Expired - Fee Related
- 2009-12-18 CA CA2747965A patent/CA2747965C/en not_active Expired - Fee Related
- 2009-12-18 CN CN200980157145.XA patent/CN102325787B/zh not_active Expired - Fee Related
- 2009-12-18 SI SI200930815T patent/SI2379580T1/sl unknown
- 2009-12-21 AR ARP090105021A patent/AR074833A1/es unknown
- 2009-12-21 TW TW098143962A patent/TWI444198B/zh not_active IP Right Cessation
-
2011
- 2011-06-19 IL IL213638A patent/IL213638A0/en unknown
- 2011-06-24 ZA ZA2011/04693A patent/ZA201104693B/en unknown
-
2013
- 2013-06-12 US US13/916,402 patent/US20140073558A1/en not_active Abandoned
-
2014
- 2014-01-09 CY CY20141100015T patent/CY1114883T1/el unknown
- 2014-03-28 SM SM201400037T patent/SMT201400037B/xx unknown
-
2015
- 2015-08-04 US US14/818,123 patent/US20150337013A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513467A5 (enExample) | ||
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| CN102871996A (zh) | 一种抗菌药物组合物及其应用 | |
| CN108823124B (zh) | 一株对革兰阳性耐药菌具有广谱抗菌活性的表皮葡萄球菌及其筛选方法和应用 | |
| Marsilio et al. | Coagulase-positive and coagulase-negative Staphylococci animal diseases | |
| JP2017519730A5 (enExample) | ||
| EP2822582B1 (en) | Multivalent vaccine protection from staphylococcus aureus infection | |
| Kazemi et al. | Antibacterial effect of silver nanoparticles along with protein synthesis-inhibiting antibiotics on Staphylococcus aureus isolated from cattle mastitis | |
| RU2004118716A (ru) | Лечение инфекции, вызываемой микроорганизмами | |
| MXPA06000691A (es) | Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables y uso de las mismas. | |
| KR101258692B1 (ko) | 항생제 저항성 포도상구균(mrsa)억제 유산균 바이셀라 비리데센스 | |
| JP2024009968A5 (enExample) | ||
| Delpech et al. | Bactericidal activity and synergy studies of peptide AP-CECT7121 against multi-resistant bacteria isolated from human and animal soft tissue infections | |
| JP2017533177A5 (enExample) | ||
| WO2013041663A3 (de) | Modifizierte apidaecinderivate als antibiotische peptide | |
| Ebani | Biology and pathogenesis of Staphylococcus infection | |
| MX2007009059A (es) | Antibiotico 107891, sus factores a1 y a2, sales y composiciones farmaceuticamente aceptables, y uso de los mismos. | |
| Bell et al. | Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008) | |
| Leite et al. | N-acetylcysteine and vancomycin alone and in combination against staphylococci biofilm | |
| Sibanda et al. | In vitro antibacterial activities of crude extracts of Garcinia kola seeds against wound sepsis associated Staphylococcus strains | |
| Jung et al. | Antibacterial activity of LCB01-0062, a novel oxazolidinone | |
| WO2009124086A3 (en) | Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections | |
| CN109620827B (zh) | 杂环丙烯酮类化合物作为抗菌剂的用途 | |
| Hussain et al. | Resistance pattern of 3rd generation cephalosporins | |
| Bhattacharyya et al. | Antibiotics business: A glimpse |